# Novo and Lilly shift GLP-1 strategy abroad: US may be next - thestreet.com

## Metadata
| Field | Value |
|-------|-------|
| Source | thestreet.com |
| URL | https://news.google.com/rss/articles/CBMilAFBVV95cUxQc25YZm02M0ZENDNEejV0eE1GZzdUQjg0Q2lTOTFQMmRPcDJocHNUM2NJZjdNV0Z1LUlUaWppaHVZRTFSdHBQeHlNVDBzRWdMUHdvVVB2N3NFVFdickR3aGkyLVhPOUhKazR2NC05Q1ZURFo5NHZpMFNhZXFtTldXRG1BQW9pWXp3TG5VcWZBakxTRkRp?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2026-01-02 12:00 |
| Category | GLP-1 |
| Relevance | 9/10 |
| Signal | bull |

## Investment Summary
Novo Nordisk and Lilly are strategically adjusting their GLP-1 market approach internationally, signaling potential expansion and market dynamics shifts in obesity and diabetes treatment markets.

## Key Entities
Novo Nordisk, Eli Lilly

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
